市场调查报告书
商品编码
1368663
粪便隐匿测试市场 - 按测试类型(癒创木脂 FOB 粪便测试、免疫 FOB 凝集测试、侧流免疫 FOB 测试、免疫 FOB ELISA 测试)、最终用途(医院、诊断中心) - 全球预测,20232- 2032Fecal Occult Testing Market - By Test Type (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test), By End-use (Hospitals, Diagnostic Centers) - Global Forecast, 20232-2032 |
由于越来越多的公众意识活动和医疗保健倡议强调早期疾病检测的重要性,粪便隐匿检测市场规模预计从 2023 年到 2032 年将复合年增长率达到 7.3%。
粪便隐匿测试技术的不断进步,例如开发更灵敏、更具体、更高准确性和可靠性的测试,正在促进市场的成长。此外,产业参与者正在实施策略性倡议,透过实施新型基因检测方法来实现癌症筛检现代化并改善医疗保健结果。举个例子,2023 年 8 月,分子遗传学诊断公司 Mainz Biomed NV 与 testDNA 合作,在波兰商业推出 ColoAlert (R),旨在为被忽视的群体提供新的创新检测替代方案。
粪便隐匿测试市场根据测试类型、最终用途和地区进行细分。
就测试类型而言,侧流免疫FOB 领域的产业价值预计将在2023 年至2032 年期间获得牵引力。这一增长可归因于这种非侵入性测试在早期检测粪便中隐藏血液中的采用率不断上升样本,作为胃肠道疾病(包括大肠癌)的重要筛检工具。使用者友善性、高敏感性和预防性医疗措施的特异性等好处也将有助于该细分市场的成长。
由于改善病患照护和诊断以提供全面的医疗保健服务,到 2032 年,医院最终用途领域的粪便隐匿检测市场规模将大幅成长。随着人们对预防保健和早期疾病检测的日益重视,医院正在采用粪便隐匿性检测作为各种胃肠道疾病(包括大肠直肠癌和胃肠道出血)的常规筛检工具。
亚太地区粪便隐匿检测市场预计从2023 年到2032 年将以显着的复合年增长率扩张。这归因于人们对胃肠道健康意识的增强、结直肠癌发病率的上升以及基于人群的筛查计划的实施。亚洲国家的几个国家癌症中心之间为建立癌症预防教育和意识的长期框架而进行的多项合作努力将影响市场的成长。例如,亚洲国家癌症中心联盟(ANCCA)拥有中国、印度、印尼、日本、韩国、蒙古、新加坡、泰国和越南等积极参与成员,规划了 2020 年至 2031 年 ANCAA 的三个部分,包括协议亚洲特定癌症登记医疗标准。
Fecal Occult Testing Market size is estimated to record 7.3% CAGR from 2023-2032 attributed to the growing number of public awareness campaigns and healthcare initiatives emphasizing the importance of early disease detection.
The ongoing advancements in fecal occult testing technologies, such as the development of more sensitive and specific tests with improved accuracy and reliability are contributing to the market growth. Furthermore, industry participants are implementing strategic initiatives to modernize cancer screening and improve healthcare outcomes through the implementation of novel genetic testing methods. To cite an instance, in August 2023, Mainz Biomed NV, a molecular genetics diagnostic firm, partnered with testDNA for the commercial launch of ColoAlert® in Poland in a bid to advance new and innovative testing alternatives to neglected groups.
The fecal occult testing market is segmented in terms of test type, end-use, and region.
With respect to test type, the industry value from the lateral flow immuno FOB segment is expected to gain traction from 2023 to 2032. The growth can be attributed to the rising adoption of this non-invasive test in the early detection of hidden blood in stool samples, serving as vital screening tool for gastrointestinal conditions, including colorectal cancer. Benefits, such as user-friendly nature, high sensitivity, and specificity in preventive healthcare measures will also contribute to the segment growth.
Fecal occult testing market size from the hospitals end-use segment will grow at significant pace by 2032 due to the presence of improved patient care and diagnostics to offer comprehensive healthcare services. With the increasing focus on preventive healthcare and early disease detection, hospitals are adopting fecal occult testing as routine screening tool for various gastrointestinal disorders, including colorectal cancer and gastrointestinal bleeding.
Asia Pacific fecal occult testing market is set to expand at notable CAGR from 2023 to 2032. This is attributed to the increasing awareness about gastrointestinal health, rising incidences of colorectal cancer, and the implementation of population-based screening programs. Several collaboration efforts among several national cancer centers in Asian countries for creating long-term framework for education and awareness about cancer prevention will influence the market growth. For instance, the Asian National Cancer Centers Alliance (ANCCA) with active participating members, such as China, India, Indonesia, Japan, Korea, Mongolia, Singapore, Thailand, and Vietnam planned three segments of ANCAA from 2020 to 2031, including the protocol for Asian-specific medical standards for cancer registries.